Tiny implant wipes out bladder cancer in 82% of patients
A new targeted drug delivery system called TAR-200 has shown remarkable results in a phase 2 clinical trial, eliminating tumors in 82% of patients with high-risk non-muscle-invasive bladder cancer that had resisted prior treatment. In most cases, the cancer disappeared within three months of therapy, and nearly half of the patients remained cancer-free one year later. "Traditionally, these patients have...









